Metastatic Colorectal Cancer (mCRC) With Matched Liver Metastases TMA

Matched Primary CRC + Liver Metastasis Tissue Microarrays for IHC & Translational Biomarker Research

Liver is the most common metastatic site in colorectal cancer, and metastatic lesions often show biological divergence from the primary tumor. If your study focuses on biomarker discovery, IHC assay validation, therapy-response signatures, or resistance mechanisms, a matched primary CRC + liver metastasis TMA enables direct paired comparison within the same patient—improving statistical power while conserving tissue.

At ArraysBank, we provide ready-to-use CRC TMAs that support fast screening, reproducible staining, and clinically meaningful interpretation, including matched liver metastasis designs.

Why Choose a Matched Liver Metastasis TMA for mCRC?

Matched primary–metastasis design helps you:

  • Evaluate biomarker concordance (primary vs metastasis)
  • Identify metastasis-enriched expression patterns
  • Validate IHC markers for patient stratification
  • Reduce confounding effects from inter-patient variability

Best-fit use cases

  • IHC assay development/optimization (antibody titration, scoring strategy)
  • Paired biomarker studies (H-score, positivity cutoff validation)
  • Exploratory translational studies (immune markers, EMT, pathway activation)
  • Method development for cross-site comparability

Featured Products (3 Options)

Below are three CRC TMA products aligned with mCRC research, including matched metastatic panels and a clinically annotated CRC TMA option.

Product 1 — DCO841: Matched Primary CRC + Liver Metastasis TMA (Duplicate Cores per case)

DCO841 is a dedicated matched-metastasis panel designed for paired comparisons.

Key specs

  • Cases / Cores: 42 cases / 84 cores
  • Design: Matched colon carcinoma + matched liver metastasis, duplicate cores per case
  • Core diameter: 1 mm
  • Section thickness: 4 µm

Best for

  • Primary vs liver metastasis concordance studies
  • IHC marker screening with duplicate-core redundancy
  • Metastasis biology exploration (paired design)

Product 2 — DCO964: Matched Primary CRC + Liver Metastasis TMA (Duplicate Cores per case)

DCO964 expands the matched-metastasis cohort size and keeps the same matched, duplicate-core concept for stronger comparisons.

Key specs

  • Cases / Cores: 48 cases / 96 cores
  • Design: Matched colon carcinoma + matched liver metastasis, duplicate cores per case
  • Core diameter: 1 mm
  • Section thickness: 5 µm

Best for

  • Larger paired analyses (higher N than DCO841)
  • Cross-validation of findings from smaller panels
  • Robust IHC reproducibility using duplicate cores

Product 3 — SMCRAC220XM: Clinically Annotated CRC TMA (Including IHC results, Molecular testing / Genetic testing, Family history, Treatment and Prognosis)

SMCRAC220XM is ideal when you want a broader CRC cohort with a strong clinical-pathologic context and a mixed composition that includes matched metastatic cases.

Key specs

  • Cases / Cores: 54 cases / 110 cores
  • Panel composition:
  • 30 cases: colon carcinoma with matched metastatic cancer
  • 13 cases: colon carcinoma with matched metastatic cancer + adjacent colon tissue
  • 11 cases: colon carcinoma
  • Core diameter: 1 mm
  • Section thickness: 5 µm

Best for

  • Studies needing grade/TNM/stage context
  • Comparing tumor vs adjacent (where available)
  • Broader CRC assay development and stratified analyses

FAQ
1. What is a matched metastasis TMA?

A matched metastasis TMA contains paired tissues—typically primary tumor and metastatic lesion from the same patient—allowing direct biological comparison within individuals.

2. Why use duplicate cores per case?

Duplicate cores improve reliability by reducing sampling bias and helping confirm staining patterns when tissue heterogeneity is present.

3. Are these TMAs suitable for IHC?

Yes. These panels are provided as TMA sections (4 µm) and are commonly used for IHC optimization, antibody validation, and biomarker screening.

4. Which product should I choose for paired primary vs liver metastasis comparisons?

If your study is specifically primary CRC vs liver metastasis, start with DCO841 or DCO964 (both are explicitly matched liver metastasis designs). Choose DCO964 when you prefer a larger cohort size.

5. Which product is best for clinical stage–stratified analyses?

Choose SM-CRAC220XM when you need pathology grade, TNM, and clinical stage built into the cohort design and want a broader CRC panel that includes matched metastatic cases.

Leave a Reply

Your email address will not be published. Required fields are marked *